Triple-Negative Breast Cancer

Key opinion leaders review clinical cases in triple-negative breast cancer, focusing on recent advances, treatment options, and clinical trials impacting the treatment.

EP. 1: Case 1: 53-Year-Old Woman With TNBC

May 27th 2021

Elizabeth Mittendorf, MD, PhD, reviews the case of a 53-year-old woman with PD-L1+ TNBC breast cancer and the panel discusses relevant clinical trial data.

EP. 2: Case 1: IMpassion 130 Trial Design and Results

May 27th 2021

Experts in breast cancer discuss efficacy data from the IMpassion130 clinical trial.

EP. 3: Case 1: KEYNOTE-355 Trial Design and Considerations

May 27th 2021

The panel of experts review the study design and key efficacy data of the KEYNOTE-355 trial.

EP. 4: Case 1: Treatment Recommendations for PD-L1+ TNBC

May 27th 2021

The panel discusses treatment options and considerations for a 53-year-old woman with PD-L1+ triple-negative breast cancer.

EP. 5: Case 2: 34-Year-Old Woman With TNBC

June 3rd 2021

Elizabeth Mittendorf, MD, PhD, presents the case of a 34-year-old woman with PD-L1–positive triple-negative breast cancer.

EP. 6: Case 2: Considerations for PARP Inhibitor Use in TNBC

June 3rd 2021

Experts in the management of breast cancer review some treatment considerations surrounding the use of PARP inhibitors in BRCA1/2–positive triple-negative breast cancer.

EP. 7: Case 2: Study Design and Data for PARP Inhibitors in TNBC

June 3rd 2021

Experts in the management of breast cancer review clinical trial data using PARP inhibitors in the treatment of BRCA1/2-mutated TNBC.

EP. 8: Case 3: 48-Year-Old Woman With Stage T2N1 TNBC

June 10th 2021

Elizabeth Mittendorf, MD, PhD, and Ruta Rao, MD, present the case of a 48-year-old woman with stage T2N1 TNBC.

EP. 9: Case 3: Implications of Residual Disease on TNBC Outcomes

June 10th 2021

Pathologist David G. Hicks, MD, discusses the impact of residual disease in breast cancer treatment outcomes.

EP. 10: Case 3: Residual Disease in TNBC and Treatment Considerations

June 10th 2021

The panel of experts share their treatment recommendations for patients with residual disease after an incomplete response to TNBC therapy.